Ticker brief
SGMO SANGAMO THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$0.1742
1 day
-0.2%
14 days
+1.3%
mkt cap
$30.7M
signals 14d
19
authors 14d
10
Sentiment — last 14 days
daily mean sentiment, 2026-06-23 → 2026-07-01 · now -0.25 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PrismMarketView | C | · | 5 | -0.34 |
| @ShortSeller | C | -0.44 | 3 | +0.55 |
| @AponiaAnalytics | B | +0.89 | 3 | -0.12 |
| @Biotech2k1 | A | +0.21 | 2 | -0.22 |
| @MartyChargin | C | -0.09 | 1 | +0.45 |
| @adamfeuerstein | A | +0.51 | 1 | -0.60 |
| @fwpharma | B | +0.22 | 1 | +0.40 |
| @PersimmonTI | A | +0.61 | 1 | -0.25 |
| @USAnt_IDEA | C | +0.40 | 1 | -0.55 |
| @BiopharmIQ | B | · | 1 | -0.35 |
Recent signals19of 19 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @AponiaAnalytics | -0.25 | Sangamo dismissed EY after Chapter 11 filing and has no replacement auditor yet. | — | tweet ↗ |
| 2026-06-30 | @PrismMarketView | +0.40 | Lists mid-day movers with large percentage gains and one decliner. | — | tweet ↗ |
| 2026-06-27 | @ShortSeller | +0.55 | Calls SGMO a crap shoot but says risk-reward is incredible with possible BP bid. | — | tweet ↗ |
| 2026-06-27 | @BiopharmIQ | -0.35 | Weekly biotech recap with multiple discrete company updates and sector themes, capped to first six tickers. | — | tweet ↗ |
| 2026-06-25 | @PrismMarketView | -0.60 | Reports mid-day movers with percentage gains and losses for listed small-cap names. | — | tweet ↗ |
| 2026-06-25 | @Biotech2k1 | +0.00 | States he did not own SGMO, implying no position exposure. | — | tweet ↗ |
| 2026-06-24 | @Biotech2k1 | -0.45 | Author dismisses SGMO fanatics after nearly 10 years of criticism. | — | tweet ↗ |
| 2026-06-24 | @ShortSeller | +0.55 | Author likes SGMO risk/reward given bankruptcy auction bids and possible Fabry asset value. | — | tweet ↗ |
| 2026-06-24 | @PrismMarketView | -0.55 | Mid-day movers list with percentage gains/losses for medtech and new energy names. | — | tweet ↗ |
| 2026-06-24 | @USAnt_IDEA | -0.55 | Reports Sangamo Chapter 11 bankruptcy filing and asset sale process. | — | tweet ↗ |
| 2026-06-23 | @PersimmonTI | -0.25 | Long biotech framework around repeat surprise, valuation, M&A and disciplined humility. | — | tweet ↗ |
| 2026-06-23 | @fwpharma | +0.40 | Lilly and Astellas bid on Sangamo assets after bankruptcy filing. | — | tweet ↗ |
| 2026-06-23 | @AponiaAnalytics | +0.10 | Sangamo 8-K/A adds asset-sale agreements; Lilly stalking-horse bid values assets at $50M. | — | tweet ↗ |
| 2026-06-23 | @AponiaAnalytics | -0.20 | Lilly and Astellas set floor bids as Sangamo enters Chapter 11; unsold assets face risk. | — | tweet ↗ |
| 2026-06-23 | @PrismMarketView | -0.55 | Mid-day movers list with AI infrastructure/cybersecurity leaders and large gains/losses. | — | tweet ↗ |
| 2026-06-23 | @PrismMarketView | -0.40 | LLY and Astellas set to acquire SGMO gene therapy assets via stalking-horse bids as SGMO files Chapter 11. | — | tweet ↗ |
| 2026-06-23 | @adamfeuerstein | -0.60 | SGMO ends with bankruptcy sale of assets; Lilly and Astellas are stalking horse bidders. | — | tweet ↗ |
| 2026-06-23 | @MartyChargin | +0.45 | Sangamo enters asset sale agreement with Lilly and Astellas amid Chapter 11. | — | tweet ↗ |
| 2026-06-23 | @ShortSeller | +0.55 | Author believes SGMO parts are worth more than liabilities as Lilly and Astellas acquire programs via auction. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.